Matthew Luchini
Stock Analyst at BMO Capital
(0.29)
# 3,022
Out of 4,497 analysts
29
Total ratings
25%
Success rate
-20.46%
Average return
Main Sectors:
Top Industries:
13 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Maintains: Outperform | $51 → $30 | $9.89 | +203.34% | 1 | Mar 18, 2022 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $190 | $20.24 | +838.74% | 1 | Oct 20, 2021 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | n/a | $37.98 | - | 3 | Sep 10, 2021 | |
| KOD Kodiak Sciences | Maintains: Market Perform | n/a | $2.87 | - | 3 | May 11, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | n/a | $6.03 | - | 1 | Mar 31, 2021 | |
| ARVN Arvinas | Initiates: Outperform | n/a | $28.52 | - | 1 | Mar 31, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | n/a | $1,063.60 | - | 7 | Jan 25, 2021 | |
| BLUE bluebird bio | Downgrades: Market Perform | n/a | $1.05 | - | 5 | Nov 5, 2020 | |
| MDGL Madrigal Pharmaceuticals | Initiates: Market Perform | n/a | $287.24 | - | 1 | Jun 5, 2020 | |
| VKTX Viking Therapeutics | Initiates: Outperform | n/a | $50.90 | - | 1 | Jun 5, 2020 | |
| GILD Gilead Sciences | Downgrades: Market Perform | n/a | $72.56 | - | 1 | Apr 20, 2020 | |
| RGLS Regulus Therapeutics | Maintains: Market Perform | n/a | $1.65 | - | 3 | Mar 8, 2018 | |
| BOLD Boundless Bio | Initiates: Outperform | n/a | $3.56 | - | 1 | Dec 5, 2017 |
Replimune Group
Mar 18, 2022
Maintains: Outperform
Price Target: $51 → $30
Current: $9.89
Upside: +203.34%
Jasper Therapeutics
Oct 20, 2021
Initiates: Outperform
Price Target: $190
Current: $20.24
Upside: +838.74%
Apellis Pharmaceuticals
Sep 10, 2021
Maintains: Outperform
Price Target: n/a
Current: $37.98
Upside: -
Kodiak Sciences
May 11, 2021
Maintains: Market Perform
Price Target: n/a
Current: $2.87
Upside: -
C4 Therapeutics
Mar 31, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.03
Upside: -
Arvinas
Mar 31, 2021
Initiates: Outperform
Price Target: n/a
Current: $28.52
Upside: -
Regeneron Pharmaceuticals
Jan 25, 2021
Upgrades: Outperform
Price Target: n/a
Current: $1,063.60
Upside: -
bluebird bio
Nov 5, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $1.05
Upside: -
Madrigal Pharmaceuticals
Jun 5, 2020
Initiates: Market Perform
Price Target: n/a
Current: $287.24
Upside: -
Viking Therapeutics
Jun 5, 2020
Initiates: Outperform
Price Target: n/a
Current: $50.90
Upside: -
Gilead Sciences
Apr 20, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $72.56
Upside: -
Regulus Therapeutics
Mar 8, 2018
Maintains: Market Perform
Price Target: n/a
Current: $1.65
Upside: -
Boundless Bio
Dec 5, 2017
Initiates: Outperform
Price Target: n/a
Current: $3.56
Upside: -